Brief: Zenas Biopharma Announces First Subject Dosed In Phase 1 Clinical Trial Of Zb021, A Novel, Potentially Best-In-Class Oral Il-17Aa/Af Inhibitor
13/05/2026 11:53
Zenas Biopharma Inc ZBIO.O: ZENAS BIOPHARMA ANNOUNCES FIRST SUBJECT DOSED IN PHASE 1 CLINICAL TRIAL OF ZB021, A NOVEL, POTENTIALLY BEST-IN-CLASS ORAL IL-17AA/AF INHIBITOR Source text: ID:nGNX3w8nkQ Further company coverage: ZBIO.O
Recent news on Zenas BioPharma
See all newsBrief: Zenas Biopharma Announces Upcoming Presentations Of Obexelimab Data In Igg4-Related Disease At The Igg4ward! 6Th International Symposium On Igg4-Related Disease And Acr Convergence 2026
Brief: Zenas BioPharma Files For Offering Of Up To 7.0 Million Shares Of Common Stock By The Selling Stockholder - SEC Filing
Zenas BioPharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Zenas Biopharma Says Phase 3 Indigo Trial Of Obexelimab Meets Primary And All Key Secondary Endpoints